MX2021004418A - Derivados de 4 pirazin 2 ilmetil-morfolina y su uso como medicamento. - Google Patents

Derivados de 4 pirazin 2 ilmetil-morfolina y su uso como medicamento.

Info

Publication number
MX2021004418A
MX2021004418A MX2021004418A MX2021004418A MX2021004418A MX 2021004418 A MX2021004418 A MX 2021004418A MX 2021004418 A MX2021004418 A MX 2021004418A MX 2021004418 A MX2021004418 A MX 2021004418A MX 2021004418 A MX2021004418 A MX 2021004418A
Authority
MX
Mexico
Prior art keywords
pyrazin
ylmethyl
medicament
morpholine derivatives
ciation
Prior art date
Application number
MX2021004418A
Other languages
English (en)
Inventor
Dieter Wiedenmayer
Roland Pfau
Angelo Ceci
Cornelia Dorner-Ciossek
Riccardo Giovannini
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2021004418A publication Critical patent/MX2021004418A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se refiere a 4-pirazin-2-ilmetil-morfolinas novedosas de la Fórmula general A (ver Fórmula) procesos para su preparación, composiciones farmacéuticas que las contienen y su uso en tratamientos, particularmente, en el tratamiento o la prevención de afecciones que tienen una relación con las propiedades de modulación alostérica negativa de NR2B.
MX2021004418A 2018-10-17 2019-10-16 Derivados de 4 pirazin 2 ilmetil-morfolina y su uso como medicamento. MX2021004418A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18200943 2018-10-17
PCT/EP2019/078027 WO2020079039A1 (en) 2018-10-17 2019-10-16 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament

Publications (1)

Publication Number Publication Date
MX2021004418A true MX2021004418A (es) 2021-07-06

Family

ID=63878518

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004418A MX2021004418A (es) 2018-10-17 2019-10-16 Derivados de 4 pirazin 2 ilmetil-morfolina y su uso como medicamento.

Country Status (36)

Country Link
US (2) US11166958B2 (es)
EP (1) EP3867244B1 (es)
JP (1) JP7093468B2 (es)
KR (1) KR20210079325A (es)
CN (1) CN112888685B (es)
AR (1) AR116711A1 (es)
AU (1) AU2019362330B2 (es)
BR (1) BR112021004993A2 (es)
CA (1) CA3113308A1 (es)
CL (1) CL2021000858A1 (es)
CO (1) CO2021004612A2 (es)
CR (1) CR20210184A (es)
DK (1) DK3867244T3 (es)
DO (1) DOP2021000069A (es)
EA (1) EA202191014A1 (es)
EC (1) ECSP21027009A (es)
ES (1) ES2940184T3 (es)
FI (1) FI3867244T3 (es)
HR (1) HRP20230249T1 (es)
HU (1) HUE061891T2 (es)
IL (1) IL282142B2 (es)
JO (1) JOP20210075A1 (es)
LT (1) LT3867244T (es)
MA (1) MA53898B1 (es)
MX (1) MX2021004418A (es)
PE (1) PE20211278A1 (es)
PH (1) PH12021550834A1 (es)
PL (1) PL3867244T3 (es)
PT (1) PT3867244T (es)
RS (1) RS63988B1 (es)
SA (1) SA521421756B1 (es)
SG (1) SG11202103806VA (es)
SI (1) SI3867244T1 (es)
TW (1) TWI828779B (es)
UA (1) UA128408C2 (es)
WO (1) WO2020079039A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11376258B2 (en) * 2019-06-04 2022-07-05 Boehringer Ingelheim International Gmbh Purine derivatives and the use thereof as medicament

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495561B2 (en) 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
CA2443108A1 (en) 2001-04-03 2002-10-17 Merck & Co. Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
MXPA04000737A (es) * 2001-07-24 2004-07-08 Richter Gedeon Vegyeszet Derivados de piperidina como antagonistas receptores de nmda.
AU2006322067A1 (en) * 2005-12-06 2007-06-14 Merck Sharp & Dohme Corp. Morpholine carboxamide prokineticin receptor antagonists
WO2010088414A2 (en) * 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor potentiators for the treatment of neurological conditions
WO2012128582A2 (en) 2011-03-23 2012-09-27 Hyundai Pharm Co., Ltd. A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
SG11201501392TA (en) 2012-10-18 2015-05-28 Hoffmann La Roche Ethynyl derivatives as modulators of mglur5 receptor activity
US9676757B2 (en) 2014-02-27 2017-06-13 Merck Patent Gmbh Heterocyclic compounds as NaV channel inhibitors and uses thereof
US10913736B2 (en) 2014-08-22 2021-02-09 University Of Washington Specific inhibitors of methionyl-tRNA synthetase
EP3362447B1 (en) * 2015-10-14 2020-08-26 Bristol-Myers Squibb Company Selective nr2b antagonists

Also Published As

Publication number Publication date
CN112888685B (zh) 2023-09-22
EP3867244B1 (en) 2023-01-18
SA521421756B1 (ar) 2023-02-12
UA128408C2 (uk) 2024-07-03
WO2020079039A1 (en) 2020-04-23
PH12021550834A1 (en) 2021-10-04
MA53898A (fr) 2022-01-26
KR20210079325A (ko) 2021-06-29
HRP20230249T1 (hr) 2023-04-14
MA53898B1 (fr) 2023-03-31
PL3867244T3 (pl) 2023-05-22
PE20211278A1 (es) 2021-07-19
CO2021004612A2 (es) 2021-04-30
JOP20210075A1 (ar) 2023-01-30
CL2021000858A1 (es) 2021-10-01
EA202191014A1 (ru) 2021-11-09
JP7093468B2 (ja) 2022-06-29
AR116711A1 (es) 2021-06-02
JP2022505080A (ja) 2022-01-14
US20200121691A1 (en) 2020-04-23
IL282142A (en) 2021-05-31
AU2019362330B2 (en) 2024-03-28
RS63988B1 (sr) 2023-03-31
EP3867244A1 (en) 2021-08-25
LT3867244T (lt) 2023-03-10
SG11202103806VA (en) 2021-05-28
SI3867244T1 (sl) 2023-04-28
US20210393644A1 (en) 2021-12-23
CA3113308A1 (en) 2020-04-23
TWI828779B (zh) 2024-01-11
US11166958B2 (en) 2021-11-09
IL282142B1 (en) 2023-12-01
ECSP21027009A (es) 2021-05-31
CN112888685A (zh) 2021-06-01
HUE061891T2 (hu) 2023-09-28
DK3867244T3 (da) 2023-05-01
BR112021004993A2 (pt) 2021-06-08
FI3867244T3 (fi) 2023-03-20
ES2940184T3 (es) 2023-05-04
TW202031262A (zh) 2020-09-01
PT3867244T (pt) 2023-02-22
AU2019362330A1 (en) 2021-04-08
IL282142B2 (en) 2024-04-01
CR20210184A (es) 2021-05-26
DOP2021000069A (es) 2021-05-31

Similar Documents

Publication Publication Date Title
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
PH12016502081A1 (en) Compounds for treating spinal muscular atrophy
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
MX2016010899A (es) A22k, desb27, b29r, des b30 en la posicion epsilon del analogo de insulina humana acilada de lisina 22.
MX2018005041A (es) Compuestos para tratar la esclerosis lateral amiotrofica.
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
MX2021006884A (es) Compuestos y su uso para el tratamiento de la deficiencia de alfa1-antitripsina.
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
ZA201805358B (en) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
CR20210460A (es) Compuestos útiles en la terapia del vih
MX2016014699A (es) (s)-pirlindol o sus sales farmaceuticamente aceptables para uso en medicina.
SA520412155B1 (ar) مشتقات إيميدازوبيريدين واستخدامها كدواء
PH12015502128A1 (en) Novel dosing regimens of celgosivir for the treatment of dengue
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12021550834A1 (en) 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
PH12020550050A1 (en) Novel acylated insulin analogues and uses thereof
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
MX2018012952A (es) Composicion oftalmica que comprende una combinacion sinergica de glucogeno y acido hialuronico o sal del mismo.
MX2015012575A (es) Novedosos derivados de acrilamida como agentes contra la malaria.